Sanofi to acquire Principia Biopharma
Further strengthens core R&D areas of autoimmune and allergic diseases
17-Aug-2020 -
Sanofi and Principia Biopharma Inc., a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for $100 per share in cash, which represents ...
acquisitions
autoimmune diseases
multiple sclerosis